Breast cancer is a leading health issue in Brazil, requiring careful consideration from both doctors and patients regarding the benefits of chemotherapy.
A study of 53 breast cancer patients revealed that a large majority are willing to undergo chemotherapy again, even for minimal benefits related to relapse, survival, or cure rates.
Factors influencing this willingness include older age, lower education levels, and not having previously received Adriamycin, indicating personal circumstances impact treatment decisions.